These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 28533923)
21. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease? Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465 [TBL] [Abstract][Full Text] [Related]
22. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study. Tran-Minh ML; Gornet JM; Maillet M; Houze P; Simon M; McLellan P; Hassid D; Vivier-Chicoteau J; Baudry C; Hammoudi N; Allez M J Crohns Colitis; 2021 May; 15(5):742-748. PubMed ID: 33205193 [TBL] [Abstract][Full Text] [Related]
23. Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study. Abushamma S; Walker T; Garza K; Chen L; Nix D; Chen CH Crohns Colitis 360; 2023 Jul; 5(3):otad022. PubMed ID: 37288326 [TBL] [Abstract][Full Text] [Related]
24. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease. Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094 [TBL] [Abstract][Full Text] [Related]
25. Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease. Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA J Crohns Colitis; 2015 Nov; 9(11):1032-42. PubMed ID: 26245216 [TBL] [Abstract][Full Text] [Related]
26. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment. Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108 [TBL] [Abstract][Full Text] [Related]
27. Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease. Babouri A; Buisson A; Bigard MA; Peyrin-Biroulet L J Crohns Colitis; 2013 Mar; 7(2):129-33. PubMed ID: 22472090 [TBL] [Abstract][Full Text] [Related]
28. Infliximab in inflammatory bowel disease. Is premedication necessary? Nuñez F P; Quera R; Simian D; Flores L; Figueroa C; Ibañez P; Kronberg U; Lubascher J; Pizarro G Gastroenterol Hepatol; 2021 May; 44(5):321-329. PubMed ID: 33386199 [TBL] [Abstract][Full Text] [Related]
29. Rapid Infliximab Infusion in Children: A Multicenter Retrospective Cohort Study. Lev-Tzion R; Assa A; Yerushalmi B; Lahad A; Friedman M; Ledder O; Turner D J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e101-e103. PubMed ID: 29064928 [TBL] [Abstract][Full Text] [Related]
30. Use of Infliximab Biosimilar Versus Originator in a Pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort. Chanchlani N; Mortier K; Williams LJ; Muhammed R; Auth MKH; Cosgrove M; Fagbemi A; Fell J; Chong S; Zamvar V; Hyer W; Bisset WM; Morris MA; Rodrigues A; Mitton SG; Bunn S; Beattie RM; Willmott A; Wilson DC; Russell RK J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):513-519. PubMed ID: 29697550 [TBL] [Abstract][Full Text] [Related]
31. Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab. Ellis LA; Malangone-Monaco E; Varker H; Stetsovsky D; Kubacki M; DeHoratius RJ; Kafka S Clinicoecon Outcomes Res; 2019; 11():99-110. PubMed ID: 30679916 [TBL] [Abstract][Full Text] [Related]
32. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy]. Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355 [TBL] [Abstract][Full Text] [Related]
33. A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn's disease. Kashima S; Sawada K; Moriichi K; Fujiya M Ther Adv Drug Saf; 2022; 13():20420986221100118. PubMed ID: 35646305 [TBL] [Abstract][Full Text] [Related]
34. Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort. Azzam N; Aljebreen A; Alharbi O; Charabaty A; Alanazi M; Alkuwaykibi N; Alfaraidi J; Bashamil A; Almansour T; Almadi M Arab J Gastroenterol; 2021 Mar; 22(1):66-72. PubMed ID: 33632623 [TBL] [Abstract][Full Text] [Related]
35. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence. Ekpu VU; Brown AK Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225 [TBL] [Abstract][Full Text] [Related]
36. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease. Huoponen S; Eberl A; Räsänen P; Roine RP; Sipponen T; Arkkila P; Blom M Medicine (Baltimore); 2020 Jan; 99(2):e18723. PubMed ID: 31914087 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience. Halpin SJ; Hamlin PJ; Greer DP; Warren L; Ford AC World J Gastroenterol; 2013 Feb; 19(7):1091-7. PubMed ID: 23467174 [TBL] [Abstract][Full Text] [Related]
38. The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care. Kuenzig ME; Lee L; El-Matary W; Weizman AV; Benchimol EI; Kaplan GG; Nguyen GC; Bernstein CN; Bitton A; Lee K; Cooke-Lauder J; Murthy SK J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S34-S41. PubMed ID: 31294383 [TBL] [Abstract][Full Text] [Related]
39. Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease. Zitomersky N; Chi L; Liu E; Bray KR; Papamichael K; Cheifetz AS; Snapper SB; Bousvaros A; Silvester JA J Pediatr Gastroenterol Nutr; 2024 Feb; 78(2):261-271. PubMed ID: 38374555 [TBL] [Abstract][Full Text] [Related]
40. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. Mazza S; Piazza O Sed N; Conforti FS; Fascì A; Rimondi A; Marinoni B; Casini V; Ricci C; Munari F; Pirola L; Invernizzi P; Girelli C; Lupinacci G; Pastorelli L; Cavallaro F; Ferraris L; Colucci A; Amato A; Eugenio Tontini G; Vecchi M; Fiorino G; Caprioli F Clin Transl Sci; 2022 Jan; 15(1):172-181. PubMed ID: 34523800 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]